Our Mission

To help patients and physicians better track and understand the effects of cannabis.

A message from our CEO

   As a neurologist, I have been increasingly faced with patients seeking to use medical Cannabis. As I tried to respond to my patients needs, I came to fully realize the number of people who suffer from afflictions that have failed all known treatments, the so called medically refractory or treatment resistant patients. It is staggering how many people live with untreated anxiety, depression, tremor, epilepsy, pain, and sleep disorders, PTSD, and traumatic brain injury. These people are desperate and they searching for relief.

   Most have explored many “alternative” therapies including supplements, accupuncture, magnetic and electrical stimulation devices, and medical Cannabis. As I began to try and understand which Cannabis molecules at which doses in which type of patients was appropriate, I hit a wall of non-information on clinical use of these molecules.

    So, in 2018, enlisted a team of software engineers, led by my talented son Mark.  Using my experience in conducting clinical trials in the epilepsy space, and Mark’s experience in creating research database software, we designed and developed Lumina, an easy to use, cloud-based clinical trial grade “tracking tool”.

Thomas Swanson, M.D. FAES

 CEO and Chief Science Officer


Thomas Swanson, MD, FAES
CEO and Chief Science Officer

Dr. Swanson has been a practicing physician for more than 30 years, and has owned and managed several neurology clinics in multiple states, including the Montana Comprehensive Epilepsy Center.

His distinguished career includes a residency at the Mayo Clinic and the prestigious Dana Neuroscience Fellowship at the University of Pennsylvania, where he studied small molecule actions in human and animal brains. Dr. Swanson went on to direct an NIH-funded basic science laboratory at the Cleveland Clinic, and has been the leading investigator on several pharmaceutical clinical trials in the epilepsy space. He is a designated “key opinion leader” by several pharmaceutical companies, and has published many original papers and book chapters in neuroscience. 

Tom holds a BS in Biology from Eastern Michigan University (1979) and an MD from Wayne State University School of Medicine (1986). He has raised 3 wonderful and successful children. Tom is also a former professional sprint class sled dog racer and a classically trained pianist. 

Mark Swanson, BA
Chief Technology Officer

Mark designs and leads all technology-related projects in Sativa Science, including Lumina, our proprietary cannabis standard-of-care software. Previously, he was a developer for the University of Michigan’s Center for Bioethics and Social Sciences in Medicine, designing their patient interface research tools. While at the Wisconsin-based Earthling Interactive, Mark supervised a team of developers working on a variety of privately funded medical software.

Mark holds a BA in Asian Studies from the University of Michigan (2009) and speaks fluent Japanese. Mark is also a former competitive ballroom dancer for the University of Michigan Ball Room Dance Team, and still enjoys dancing and teaching dance. Mark began studying classical piano at an early age at the Cleveland Settlement Music School and later at the Fireland’s Symphony Orchestra Music School, and the Bowling Green State University School of Music. He is an accomplished musician, singer, and songwriter, having performed with other great artists such as Michael Buble and the Cleveland Pops Orchestra. Marks music is available on iTunes under his band name “Origami Incident”.

Mark also enjoys raising his wonderful daughter, skiing, playing hockey, building things, and of course piano and dance. 


Jacci Bainbridge PharmD, FCCP, MSCS, FAES
Professional Advisory Board Director

An experienced clinical pharmacy specialist, Dr. Bainbridge is an expert on brain drug interactions and metabolism. Dr. Bainbridge is at the forefront of cannabinoid pharmacologic development, a national thought leader on cannabinoid drug interactions, an advocate for scientific use of cannabinoids, as well as a frequent speaker at national cannabinoid conventions.

Currently, Dr. Bainbridge’s research involves compounding novel cannabinoid molecule formulations that are tested in FDA approved clinical trials. Most recently she has published on the safety and tolerability of cannabidiol in Parkinson’s disease. She is part of a clinical trial team conducting research in back pain, restless legs syndrome, multiple sclerosis, Parkinson’s disease, fragile X syndrome, and autism spectrum disorder.

Paul Lyons MD, PhD, FAES, FAAN
Professional Advisory Board Member

Dr. Paul Lyons is the Founder and Director of the Virginia Comprehensive Epilepsy and Neurodevelopment Clinic. As an epileptologist and neuroscientist with decades of experience in treating neurological disorders.

He is currently investigating new technology to improve brain cannabinoid molecule delivery in preclinical studies using a rodent model of Alzheimer’s Disease. He also has extensive experience in designing clinical drug trials and has published articles in numerous scientific journals. Licensed in Virginia, New York and the State of Washington, he is Board Certified in Neurology, Sleep Medicine, Clinical Neurophysiology and Epilepsy.

In addition to his interest in medical marijuana, he focuses on epilepsy surgery, neuropsychological, psychiatric, and behavioral consequences of epilepsy, biomedical devices, novel class of molecules research for treatment of pharmacologically refractory epilepsy, sleep disturbances, neuroimmunology and neurophysiology. Dr. Lyons graduated from medical school at the University of Alabama at Birmingham and trained at the University of Virginia.

John Mendelson MD
Professional Advisory Board Member

Dr. John Mendelson is the Chief Medical Officer and Founder of Ria Health, (formerly DxRx), an alcohol addiction treatment center based in San Francisco. As a Board Certified Internist with over 30 years of research and practice in the field of addiction, Dr. Mendelson brings his commitment to evidence-based treatment to Sativa Science.

Born of his strong conviction that patients should have access to safe, effective and affordable addiction treatment, Dr. Mendelson’s formula for compassionate addiction treatment combines science based methods with new technology, medication, recovery and coaching.

He has worked with patients in his private practice for several decades, and recently served as Medical Director of BAART (Bay Area Addiction Research and Treatment) where he supervised 5 opioid treatment clinics in San Francisco. He believes that success can and should be measured by scientific data and to that end, Dr. Mendelson is a seasoned research professional. He was Medical Director of the Drug Dependence Research Center at UCSF from 1991 to 2007, as well as Founder and Director of the Addiction and Pharmacology Research Laboratory at California Pacific Medical Center from 2004 to 2016. More recently, he has acted as Senior Research Scientist at Friends Research Institute. He also currently serves as Clinical Professor of Medicine at University of California, San Francisco (UCSF). 

David Anschel MD
Professional Advisory Board Member

Dr. Anschel is the founding director of the St. Charles Epilepsy Center, an affiliate of the NYU Comprehensive Epilepsy Center at St. Charles Hospital in Port Jefferson, NY and is the Director of Epilepsy and EEG Services at Good Samaritan Hospital in West Islip, NY. Dr. Anschel also serves as Adjunct Associate Professor at New York University School of Medicine. He currently has over 90 scientific and technical publications, and holds Board Certifications in Neurology, Clinical Neurophysiology, and Epilepsy.

Dr. Anschel earned his B.S. in Biological Sciences, summa cum laude, from the State University of New York at Buffalo. He then went on to earn an M.D., with Honors in Physiology and Neuroscience, from New York University School of Medicine. He completed his neurology residency at Harvard University-Beth Israel Deaconess Medical Center/Boston Children’s Hospital, followed by a fellowship in epilepsy and clinical neurophysiology at Stanford University.

Ann DeWerth JD
Branding & Communications Lead

Ann DeWerth is a practicing attorney in the legal cannabis industry.

Ann graduated from NYU with a BA in English and French literature. She then studied at Sorbonne in Paris earning a Certificate in French Language, before graduating from Columbia University with a Masters in Journalism.

After college, Ann worked as a journalist and then as a creative, public relations, and marketing executive who represented internationally known brands, athletes, and events, such Derek Jeter, Tiger Woods, the Cleveland Grand Prix, and Stars on Ice. Ann then attended Cleveland Marshall College of Law and has been a practicing attorney for over a decade. Ann has been instrumental in developing our brand and formulating our initial marketing efforts. 

Laura Perkovic JD
Professional Advisory Board Member

Laura A. Perkovic is a health care attorney who brings twenty-one years of courtroom experience in criminal and civil cases, including health care fraud and abuse, to Sativa Science. She previously served as a Special Assistant United States Attorney and Deputy Attorney General for a state Medicaid Fraud Control Unit.

In private practice, she represented physicians, pharmacists, nurses, clinics, pharmacies, and other health care providers and organizations in regulatory compliance, transactions, and the defense of government investigations and prosecutions. She currently serves as Chief Legal Officer for one of the largest independent medical practices in the country.